医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CLARIUM Lens Launches a Wider Range of Premium Quality Lens Products

2019年08月14日 AM10:18
このエントリーをはてなブックマークに追加


 

SINGAPORE

Clarium Lens, a technological innovator in the field of optics, extends its range of Clarium Lux lens products. The Clarium Lux range is designed to address the growing number of vision problems that limit visual perception.

The company offers different lens options for specific applications. Clarium Single Vision lenses are fitted for either reading distance or looking into the distance. Multifocal lenses incorporate the near, intermediate, and distance zones in one lens with smooth transitions. Digital or Blue Light Filter lenses shield the eyes from blue light emitted by smartphones, tablets and other screen devices. Other lens options include High Index, Anti-Glare, Photochromic and Scratch Resistant lenses.

Clarium Lens is committed to providing its customers with trusted, quality lens products that are designed and manufactured with cutting edge technology. Focused on producing high caliber products, Clarium delivers its lenses only after extensive quality checks to ensure quality and comfort in its range of premium lenses.

All Clarium lenses are made from premium engineered polymers formed under strict quality controlled conditions in a medically certified laboratory (ISO 13485). The laboratory employs 1,200 highly experienced staff in the field.

For more information, you can visit the website, www.clariumlens.com. Alternatively, you can reach out through email at info@clariumlens.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190813005809/en/

CONTACT

Ino Tumamao

info@clariumlens.com

(02) 8355 4646

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024